"CBD Deep Dive" | Cannabinoid Market Insights

The discussion delved into the science of CBD, highlighting its non-psychotropic nature and interaction with the endocannabinoid system. Key findings included a 2019 Shannon case series showing 80% anxiety reduction with CBD, and a 2023 Arnold review indicating effectiveness at 300-400 mg for anxiety but not pain. Sleep effects were complex, with some studies showing improvements and others reporting insomnia. CBD's safety profile was generally favorable, but common side effects included GI issues, sleep changes, and liver enzyme increases. The conversation also emphasized the need for caution due to potential drug interactions and the variability in CBD products.